[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100178353":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":17,"locations":23,"responsibleParty":28,"collaborators":17,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":17,"eligibilityCriteria":36,"healthyVolunteers":37,"sex":38,"minAge":39,"maxAge":17,"enrollmentInfo":40,"targetDuration":17,"studyType":43,"phases":44,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":53,"whyStopped":17,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":17,"completionDateStruct":17,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug: Dexrazoxane","EXPERIMENTAL","Dexrazoxane should be given once daily for 3 consecutive days. The dose is:\n\nDay 1: 1000 mg\u002Fm2, Day 2: 1000 mg\u002Fm2, Day 3: 500 mg\u002Fm2 (body surface area)",[9],[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":17},"DRUG","Dexrazoxane",null,[9],[20],{"name":21,"affiliation":5,"role":22},"Tatsuro Takei","STUDY_DIRECTOR",[24],{"facility":25,"status":17,"city":26,"state":17,"zip":17,"country":25,"countryCode":27,"cosmosGeoPoint":17,"geoPoint":17,"contacts":17},"Japan","Tokyo and Other Japanese City","JP",{"type":29,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100178353","phase-1-a-phase-iii-study-of-kdx-0811dexrazoxane-in-the-treatment-of-accidental-extravasation-of-anthracycline-anti-cancer-agents-100178353",true,"NCT01596088","A Phase I\u002FII Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents","A Multicenter, Open Label, Single-arm Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents","Inclusion Criteria:\n\n* Patients suspected to have been exposed to extravasation of anthracycline\n\nExclusion Criteria:\n\n* Patients reasonably suspected to have been exposed to extravasation by other compounds than anthracyclines through the same IV access, e.g. vincristine, mitomycin, and vinorelbine, all of which may cause ulceration",false,"ALL","20 Years",{"count":41,"type":42},2,"ACTUAL","INTERVENTIONAL",[45,46],"PHASE1","PHASE2","The purpose of this study is to evaluate the efficacy and safety of KDX-0811(Dexrazoxane) in the treatment of accidental extravasation of anthracycline anti-cancer agents.",[49],"Extravasations of Anthracycline Anti-cancer Agents",[51,52],"Extravasation","Anthracyclines","COMPLETED","2015-03-18",{"date":56,"type":57},"2015-04-07","ESTIMATED",{"name":5,"class":6},1]